Safety of nivolumab/pembrolizumab in hepatitis B surface antigen-positive non-small cell lung cancer (NSCLC) patients.

被引：0
|
作者：
Xu, Chongrui
Tu, Hai-Yan
Sun, Yue-Li
Li, Yang-Si
Xu, Bing-Fei
Wang, Bin-Chao
Chen, Hua-Jun
Wang, Zhen
Zhou, Qing
Yang, Jin-Ji
Wu, Yi-Long
机构：
[1] South China Univ Technol, Sch Med, Guangdong Acad Med Sci, Guangdong Lung Canc Inst,Guangdong Prov Peoples H, Guangzhou, Guangdong, Peoples R China
[2] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Guangdong Lung Canc Inst, Guangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21670
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Immune Checkpoint Inhibition for Non-Small Cell Lung Cancer (NSCLC) in Patients with Pulmonary Tuberculosis or Hepatitis B
    Chan, G.
    Huang, Y. Q.
    Ang, Y.
    Chong, W. Q.
    Muthu, V.
    Wong, A.
    Soo, R.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S722 - S722
  • [22] Phase II study of nivolumab in patients with advanced non-small cell lung cancer (NSCLC) in Korea
    Cho, E. K.
    Kang, J. H.
    Han, J-Y.
    Lee, J. S.
    Kim, D-W.
    Kim, S-W.
    Min, Y. J.
    Lee, K. H.
    Kim, J-H.
    Park, K.
    ANNALS OF ONCOLOGY, 2017, 28
  • [23] Single-center experience with nivolumab in pretreated patients with non-small cell lung cancer (NSCLC).
    Rapoport, Bernardo Leon
    Smit, Teresa
    van Eeden, Ronwyn
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (07)
  • [24] Nivolumab in Non-Small Cell Lung Cancer (NSCLC): The Real-Life Data
    Dudnik, Elizabeth
    Moskovitz, Mor
    Daher, Sameh
    Shamai, Sivan
    Hanovich, Ekaterina
    Shechtman, Yelena
    Abu-Amna, Mahmoud
    Zer, Alona
    Wollner, Mira
    Bar, Jair
    Merimsky, Ofer
    Cyjon, Arnold
    Shochat, Tzippy
    Peled, Nir
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S417 - S418
  • [25] Nivolumab in Non-Small Cell Lung Cancer (NSCLC): A Real-Life Study
    Reis, D.
    Mendes, A.
    China, N.
    Dias, M.
    Coutinho, D.
    Silva, E.
    Campainha, S.
    Costa, T.
    Conde, S.
    Barroso, A.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S975 - S976
  • [26] Non-small cell lung cancer (NSCLC) in elderly patients
    Batura-Gabryel, H.
    Brajer, B.
    LUNG CANCER, 2006, 52 : S19 - S19
  • [27] Safety of pembrolizumab in patients with non-small cell lung cancer: a real-world study
    Thakrar, D. B.
    Essang, B.
    Echlin, A.
    Murdock, C.
    Lind, M. J.
    LUNG CANCER, 2019, 127 : S40 - S41
  • [28] Advanced non-small cell Lung Cancer (NSCLC) Nivolumab in advanced NSCLC with Squamous Epithelial Histology
    Sankawa, Yuri
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 (03) : 149 - 149
  • [29] Optimum timing of gefitinib therapy in metastatic non-small cell lung cancer (NSCLC) patients.
    Ayllon, J
    Plazanet, V
    Guillevin, EF
    Banu, E
    Bonan, B
    Oudard, S
    Barthes, FP
    Theou, N
    Sors, H
    Andrieu, JM
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 700S - 700S
  • [30] EFFECTIVENESS AND SAFETY OF PEMBROLIZUMAB IN ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
    Murteira, R.
    Ramos, C.
    Cardoso Borges, F.
    Ferreira, M. M.
    Miranda, A.
    da Costa, Alves F.
    VALUE IN HEALTH, 2018, 21 : S15 - S15
12345